Theralase Technologies CEO Roger DuMoulin-White joined Steve Darling from Proactive to share news the company has shared interim data from a Phase II clinical study which was designed to treat patients diagnosed with Bacillus Calmette-Guérin Unresponsive, Non-Muscle Invasive Bladder Cancer and Carcinoma In-Situ with a patented investigational study drug Ruvidar subsequently activated by a proprietary investigational study laser system equipped with fiber-optic light emitters and detectors. DuMoulin-White telling Proactive more about the study and what the interim data is telling them about the study. White also talked about the company and the other vertical the company has with its Cool Laser Therapy which is focused on the research, development, production and distribution of medical laser technologies for healing pain.
Theralase Technologies share positive interim results from Phase II Bladder Cancer study
